News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NanoString Technologies Inc. Announces Oral Study Presentation of the Prosigna™ Assay in Postmenopausal Node-Positive Breast Cancer at the 2013 Annual American Society of Clinical Oncology



5/16/2013 8:44:06 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that a clinical study of the Prosigna Breast Cancer Assay will be presented during the Breast Cancer Oral Abstract Session at the 2013 Annual American Society of Clinical Oncology (ASCO) Meeting on Sunday, June 2.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES